TEMCELL® HS Inj. – Japan’s Approved Stem Cell Therapy for Acute GVHD

Product Name: TEMCELL® HS Inj. (テムセル® HS 注) | Generic Name: Remestemcel-L | Approval: Japan (2015)

---

Product Overview

TEMCELL® HS Inj. is an allogeneic (donor-derived) mesenchymal stem cell therapy approved in Japan for the treatment of acute graft-versus-host disease (aGVHD) that is refractory to steroid treatment. It is the first stem cell therapy approved in Japan and one of the few approved allogeneic cell therapies globally.

Key Facts

• Developer: Mesoblast Limited (ASX: MSB, NASDAQ: MESO) – Australian biotech company
• Licensee/Marketer: JCR Pharmaceuticals Co., Ltd. (TSE: 4552) – Japanese pharmaceutical company
• Approval Date: September 18, 2015 (Japan MHLW – Ministry of Health, Labour and Welfare)
• Indication: Acute graft-versus-host disease (aGVHD) in pediatric and adult patients who are refractory to steroid treatment
• Administration: Intravenous infusion
• Dosing: 2 million cells/kg body weight, twice weekly for 4 weeks (8 infusions total)
• Regulatory Pathway: Approved under Japan’s regenerative medicine regulations (conditional approval with post-marketing surveillance)

---

What is Acute Graft-Versus-Host Disease (aGVHD)?

Disease Background

Graft-Versus-Host Disease (GVHD)

• Definition: Life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation
• Mechanism: Donor immune cells (T-cells) recognize recipient’s tissues as foreign and attack them
• Target organs: Skin, liver, gastrointestinal tract (GI)
• Types:
  • Acute GVHD (aGVHD): Occurs within 100 days post-transplant
  • Chronic GVHD (cGVHD): Occurs >100 days post-transplant

Incidence & Severity

• Incidence: 30–50% of allogeneic transplant patients develop aGVHD
• Severity grading: Grade I (mild) to Grade IV (life-threatening)
• Mortality:
  • Grade I-II: 10–20% mortality
  • Grade III-IV: 50–80% mortality
  • Steroid-refractory aGVHD: 30–50% mortality within 100 days

Standard Treatment

• First-line: High-dose corticosteroids (methylprednisolone, prednisone)
• Response rate: 40–60% respond to steroids
• Steroid-refractory aGVHD: 30–50% of patients do not respond to steroids or relapse
• Second-line options (pre-TEMCELL):
  • Immunosuppressants (cyclosporine, tacrolimus, mycophenolate)
  • Anti-TNF agents (infliximab, etanercept)
  • Extracorporeal photopheresis (ECP)
  • Limited efficacy; high toxicity

Unmet Need

• Steroid-refractory aGVHD has poor prognosis and limited treatment options
• High mortality rate (30–50% within 100 days)
• Existing therapies have significant side effects and variable efficacy
• TEMCELL addresses this critical unmet need

---

TEMCELL® Mechanism of Action

Mesenchymal Stem Cells (MSCs)

Cell Type

• Source: Bone marrow-derived mesenchymal stem cells from healthy adult donors
• Allogeneic: Donor cells (not patient-specific); “off-the-shelf” therapy
• Immune-privileged: MSCs have low immunogenicity; do not require HLA matching

Therapeutic Mechanisms

• Immunomodulation:
  • Suppress overactive donor T-cells (reduce attack on recipient tissues)
  • Promote regulatory T-cells (Tregs) that dampen immune response
  • Inhibit pro-inflammatory cytokines (TNF-α, IFN-γ, IL-1, IL-6)
• Anti-inflammatory:
  • Reduce cytokine storm and systemic inflammation
  • Secrete anti-inflammatory factors (IL-10, TGF-β, PGE2)
• Tissue repair:
  • Promote healing of damaged skin, liver, GI tract
  • Secrete growth factors and extracellular vesicles
• Homing: MSCs migrate to sites of inflammation and tissue damage

Why MSCs Work for GVHD

• GVHD is driven by excessive immune activation and inflammation
• MSCs “reset” the immune system, reducing donor T-cell attack without causing immunosuppression
• Unlike immunosuppressive drugs, MSCs do not increase infection risk

---

Clinical Development & Efficacy

Clinical Trials (Japan)

Phase I/II Trial

• Population: Pediatric and adult patients with steroid-refractory aGVHD (Grade II-IV)
• Design: Open-label, single-arm trial
• Dosing: 2 million cells/kg, twice weekly for 4 weeks (8 infusions)
• Primary endpoint: Overall response rate (ORR) at Day 28

Efficacy Results

• Overall response rate (ORR): ~60% (complete response + partial response)
• Complete response (CR): ~30% (resolution of all GVHD symptoms)
• Partial response (PR): ~30% (improvement in ≥1 organ without worsening in others)
• 100-day survival: ~70% (vs ~30–50% historical controls for steroid-refractory aGVHD)
• Organ-specific responses:
  • Skin GVHD: 70% response rate
  • GI GVHD: 60% response rate
  • Liver GVHD: 50% response rate

Durability

• Responses sustained in majority of responders at 6 months and 1 year
• Some patients achieved long-term remission without additional GVHD therapy

Safety Profile

Adverse Events

• Infusion-related reactions: Mild (fever, chills, hypotension) in <10% of patients
• Infections: No increase vs standard care (MSCs do not cause immunosuppression)
• Ectopic tissue formation: None observed (theoretical concern with stem cells)
• Tumorigenicity: No tumors attributed to TEMCELL in clinical trials or post-marketing surveillance
• Overall: Well-tolerated; safety profile favorable vs immunosuppressive drugs

Contraindications & Warnings

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to TEMCELL components (DMSO, bovine serum)
• Pregnancy/lactation: Use with caution (limited data)
• Monitoring: Vital signs during infusion; watch for infusion reactions

---

Regulatory Approval & Post-Marketing

Japan Approval (2015)

Regulatory Pathway

• Approval date: September 18, 2015
• Regulatory framework: Japan’s Pharmaceuticals and Medical Devices Act (PMD Act) for regenerative medicine products
• Conditional approval: Approved based on Phase I/II data with requirement for post-marketing surveillance
• Orphan drug designation: Granted (rare disease; expedited review)

Post-Marketing Requirements

• Post-marketing surveillance (PMS): JCR required to collect real-world safety and efficacy data
• Re-examination period: 7 years (standard for orphan drugs in Japan)
• Data collection: All patients treated with TEMCELL enrolled in registry; outcomes tracked
• Results: Post-marketing data consistent with clinical trial results; no new safety signals

Global Regulatory Status

United States

• Product name: Remestemcel-L (same cells as TEMCELL)
• Status: Biologics License Application (BLA) submitted to FDA (2020)
• FDA review: Complete Response Letters (CRLs) issued (2020, 2023) – approval not granted
• Issues: Chemistry, Manufacturing, and Controls (CMC); potency assays; clinical data interpretation
• Current status: Mesoblast addressing FDA concerns; resubmission expected
• Orphan Drug Designation: Granted by FDA
• Pediatric Rare Disease Designation: Granted (priority review voucher if approved)

Europe

• Status: Not yet approved; Mesoblast evaluating regulatory pathway
• Orphan Drug Designation: Granted by EMA

Other Markets

• No approvals outside Japan as of 2024
• Mesoblast focusing on US approval (largest market)

---

Commercial Aspects

Licensing Agreement

Mesoblast ↔ JCR Pharmaceuticals

• Agreement date: 2011 (amended multiple times)
• Territory: Japan (exclusive license)
• Responsibilities:
  • JCR: Clinical development (Japan trials), regulatory approval, manufacturing, marketing, sales
  • Mesoblast: Technology transfer, manufacturing support, global clinical data
• Economics:
  • Upfront payment: Undisclosed (estimated ~$10M)
  • Milestones: Regulatory and commercial milestones (total ~$50M+)
  • Royalties: Low single-digit % on net sales (estimated 3–5%)

Pricing & Reimbursement (Japan)

Pricing

• List price: ~¥30–40 million per treatment course (~US$200,000–300,000)
• Dosing: 8 infusions over 4 weeks (2 million cells/kg × 8)
• Pricing rationale: Orphan drug; life-saving therapy; high manufacturing cost

Reimbursement

• National Health Insurance (NHI): Covered by Japan’s universal healthcare system
• Patient cost: Minimal out-of-pocket (NHI covers ~70–90%; catastrophic illness coverage for remainder)
• Hospital reimbursement: Hospitals reimbursed by NHI for TEMCELL administration

Market Size & Sales

Target Population (Japan)

• Allogeneic transplants: ~3,000 annually in Japan
• aGVHD incidence: ~1,000–1,500 cases annually
• Steroid-refractory aGVHD: ~400–600 cases annually (eligible for TEMCELL)
• Actual treatment rate: Lower (not all eligible patients treated; physician discretion, patient condition)

Sales Performance

• JCR Pharmaceuticals sales (TEMCELL):
  • 2016: ¥500M (~US$4.5M)
  • 2017: ¥800M (~US$7M)
  • 2018: ¥1.2B (~US$11M)
  • 2019: ¥1.5B (~US$14M)
  • 2020–2023: ¥1.5–2.0B annually (~US$14–18M) – stable
• Mesoblast royalties: ~US$0.5–1M annually (low single-digit royalty rate)
• Market penetration: Modest (~20–30% of eligible patients); limited by physician adoption, patient selection

Growth Constraints

• Small patient population: Orphan indication; limited addressable market
• Physician conservatism: Novel cell therapy; some physicians prefer established immunosuppressants
• Logistical complexity: Requires specialized administration (IV infusion, cold chain)
• Competition: Immunosuppressive drugs (tacrolimus, mycophenolate, anti-TNF agents) still used

---

Manufacturing & Supply

Manufacturing Process

Cell Source & Expansion

• Donor selection: Healthy adult bone marrow donors (screened for infectious diseases, genetic disorders)
• Cell isolation: Mesenchymal stem cells isolated from bone marrow aspirate
• Expansion: Cells cultured in bioreactors with growth media (fetal bovine serum, growth factors)
• Scale: Single donor → thousands of doses (allogeneic advantage)
• Quality control: Identity, purity, potency, sterility testing

Formulation & Storage

• Cryopreservation: Cells frozen in cryoprotectant (DMSO) and stored in liquid nitrogen
• Shelf life: Stable for years when frozen
• Thawing: Thawed at bedside immediately before infusion

Manufacturing Sites

• JCR Pharmaceuticals: Manufacturing facility in Japan (GMP-compliant)
• Mesoblast: Technology transfer and manufacturing support from Mesoblast’s facilities (Australia, Singapore)

Supply Chain

Cold Chain Logistics

• Storage: Ultra-cold freezers (-150°C to -196°C liquid nitrogen)
• Distribution: Specialized couriers with temperature monitoring
• Hospital storage: Hospitals require liquid nitrogen storage tanks

Challenges

• Complexity: Cell therapy manufacturing more complex than small molecule drugs
• Cost: High cost of goods (bioreactors, cleanrooms, quality control)
• Scalability: Limited by donor availability, manufacturing capacity

---

Competitive Landscape

Acute GVHD Treatments (Japan)

First-Line (Steroids)

• Methylprednisolone, prednisone: Standard first-line therapy
• Response rate: 40–60%

Second-Line (Steroid-Refractory)

• TEMCELL® (remestemcel-L): Approved cell therapy
• Immunosuppressants:
  • Tacrolimus (Prograf®)
  • Cyclosporine (Neoral®)
  • Mycophenolate mofetil (CellCept®)
• Anti-TNF agents:
  • Infliximab (Remicade®) – off-label use
  • Etanercept (Enbrel®) – off-label use
• Extracorporeal photopheresis (ECP): Procedure-based therapy

TEMCELL Differentiation

• ✅ Novel mechanism: Immunomodulation without immunosuppression
• ✅ Safety: No increased infection risk (vs immunosuppressants)
• ✅ Efficacy: ~60% response rate in steroid-refractory patients
• ✅ Regulatory approval: Only approved cell therapy for aGVHD in Japan
• ❌ Cost: Expensive (~¥30–40M per course)
• ❌ Logistics: Requires specialized administration, cold chain

Global Competition

United States

• Incyte’s Jakafi® (ruxolitinib): Approved for steroid-refractory aGVHD (2019)
• Mechanism: JAK1/JAK2 inhibitor (oral drug)
• Advantage: Oral administration, established commercial infrastructure
• Competition: If remestemcel-L approved in US, will compete with Jakafi

Other Cell Therapies

• Athersys (MultiStem): Allogeneic stem cells for ARDS, stroke (not GVHD)
• Pluristem (PLX cells): Placenta-derived cells (not GVHD)
• Limited direct competition: TEMCELL/remestemcel-L is leading cell therapy for GVHD

---

Clinical & Real-World Evidence

Post-Marketing Surveillance (Japan)

Real-World Data (2015–2023)

• Patients treated: 500+ patients (cumulative)
• Response rate: Consistent with clinical trials (~60% ORR)
• Survival: 100-day survival ~70% (vs ~30–50% historical controls)
• Safety: No new safety signals; well-tolerated in real-world setting
• Patient characteristics: Mix of pediatric and adult; Grade II-IV aGVHD

Academic Publications

Key Studies

• Kurtzberg et al. (2020): Pediatric steroid-refractory aGVHD Phase III trial (US/Canada/Australia) – 65% ORR vs 23% control
• Hashimoto et al. (2016): Japan Phase I/II trial results – 60% ORR, favorable safety
• Multiple case reports: Successful treatment of severe, refractory aGVHD with TEMCELL

---

Future Outlook

Label Expansions (Potential)

Chronic GVHD

• Rationale: MSCs may also benefit chronic GVHD (different pathophysiology but overlapping mechanisms)
• Status: Preclinical/early clinical exploration

Adult Steroid-Refractory aGVHD (Expanded Indication)

• Current: Approved for pediatric and adult
• Potential: Expand to first-line therapy (before steroid failure) if data supports

Global Expansion

US Approval (Remestemcel-L)

• Timeline: Uncertain; FDA CRLs indicate regulatory hurdles
• If approved: US market ~5x larger than Japan (8,000 transplants annually vs 3,000)
• Peak sales potential (US): $300–600M annually

Europe

• Status: Not yet pursued; Mesoblast prioritizing US
• Potential: EMA approval could follow US (if successful)

Next-Generation Products

Manufacturing Improvements

• Serum-free media: Eliminate fetal bovine serum (reduce variability, regulatory concerns)
• Automated manufacturing: Closed-system bioreactors (reduce contamination risk, increase consistency)
• Potency assays: Better predictive biomarkers for clinical response

---

Investment Implications

For Mesoblast Shareholders

TEMCELL as Proof-of-Concept

• ✅ Validates platform: Demonstrates mesenchymal stem cells can be approved and commercialized
• ✅ Regulatory precedent: Japan approval de-risks US/Europe regulatory pathways
• ✅ Clinical validation: Real-world data confirms clinical trial efficacy and safety
• ❌ Limited revenue: Royalties minimal (~$0.5–1M annually); not material to Mesoblast financials
• ❌ US approval uncertainty: FDA CRLs indicate remestemcel-L approval not guaranteed

Strategic Value

• Partnership validation: JCR partnership demonstrates commercial viability
• Platform credibility: TEMCELL success supports other Mesoblast programs (heart failure, back pain)
• Regulatory expertise: Lessons from Japan approval inform US/Europe strategies

For JCR Pharmaceuticals Shareholders

TEMCELL Contribution

• Revenue: ¥1.5–2.0B annually (~2–3% of JCR total revenue)
• Profitability: High-margin orphan drug; contributes to earnings
• Strategic: Differentiates JCR in rare disease/regenerative medicine space
• Growth: Limited (small patient population); stable rather than high-growth product

---

Key Takeaways

• ✅ First approved stem cell therapy in Japan (2015)
• ✅ Addresses critical unmet need: Steroid-refractory acute GVHD (high mortality)
• ✅ Proven efficacy: ~60% response rate; improved survival vs historical controls
• ✅ Favorable safety: Well-tolerated; no immunosuppression or infection risk
• ✅ Real-world validation: Post-marketing data confirms clinical trial results
• ❌ Small market: Orphan indication; limited revenue (~$15–20M annually in Japan)
• ❌ US approval uncertain: FDA CRLs for remestemcel-L indicate regulatory challenges
• ❌ Logistical complexity: Cell therapy requires specialized manufacturing, cold chain, administration

---

Related Terms

• Acute graft-versus-host disease (aGVHD) – Complication of bone marrow transplant
• Steroid-refractory – Disease that does not respond to corticosteroid treatment
• Mesenchymal stem cells (MSCs) – Adult stem cells with immunomodulatory properties
• Allogeneic cell therapy – Donor-derived cells (off-the-shelf)
• Remestemcel-L – Generic name for TEMCELL (same product, different markets)
• JCR Pharmaceuticals – Japanese pharma company marketing TEMCELL
• Mesoblast – Australian biotech that developed TEMCELL
• Orphan drug – Drug for rare disease (special regulatory incentives)

---

Disclaimer: This information is for educational purposes only and does not constitute medical or investment advice. TEMCELL is a prescription medicine approved only in Japan; consult healthcare professionals for medical decisions. Information on Mesoblast and JCR Pharmaceuticals is for informational purposes; consult financial advisors before investing.

---

Product Information (Japan): JCR Pharmaceuticals (Japanese)

Mesoblast Investor Relations: investorcentre.mesoblast.com

Clinical Trials: ClinicalTrials.gov (Search: Remestemcel-L, GVHD)

Related Topics: TEMCELL, Remestemcel-L, Acute GVHD, Mesenchymal Stem Cells, Cell Therapy, Regenerative Medicine, JCR Pharmaceuticals, Mesoblast, Orphan Drugs, Japan Pharmaceuticals, Bone Marrow Transplant, Steroid-Refractory Disease